Alfasigma Wins EU Approval for Filgotinib in axSpA
Milan, Italy, November 5, 2026 Alfasigma S.p.A., a global pharmaceutical company focused on innovative treatments for specialty care and...
rheumatology
Advertisement
SetPoint Medical Expands RA Neuroimmune Therapy Access
Atlantic City, New Jersey, U.S., September 28, 2026 SetPoint Medical has announced an important clinical-access milestone following the completion...
Johnson & Johnson Reports TREMFYA Axial PsA Study Data
Spring House, Pennsylvania, September 25, 2026 Johnson & Johnson announced topline results from the Phase 4 STAR study evaluating...
Amgen Reports Positive Phase 3 Dazodalibep Results
Thousand Oaks, California, U.S., September 22, 2026 Amgen has announced positive topline results from the pivotal Phase 3 OASIZ...
AbbVie Wins EU Approval for RINVOQ in Pediatric JIA
North Chicago, Illinois, U.S., September 22, 2026 AbbVie has announced that the European Commission has approved RINVOQ® (upadacitinib) for...
Advertisements
Alfasigma Gains Positive CHMP Opinion for Filgotinib in axSpA
MILAN, Italy — September 18, 2026 Alfasigma announced that the Committee for Medicinal Products for Human Use (CHMP) of...
Novartis Advances Cosentyx for Polymyalgia Rheumatica
Basel, Switzerland, September 18, 2026 Novartis has announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
Bristol Myers Squibb Reports Durable Sotyktu Results in PsA
PRINCETON, N.J. — September 17, 2026 Bristol Myers Squibb announced positive two-year results from the Phase 3 POETYK PsA-2...
SetPoint Medical Expands RA Neuroimmune Therapy in Oregon
Valencia, California, USA, September 16, 2026 SetPoint Medical announced that Oregon Health & Science University (OHSU) has become the...
Lupus Foundation Awards Grants to Advance Targeted Research
New York and Massachusetts, USA, August 14, 2026 The Lupus Foundation of America has announced the recipients of its...
Advertisement
